This trial is active, not recruiting.

Condition cancer
Treatment exercise based on active video gaming
Sponsor Turku University Hospital
Collaborator University of Turku
Start date January 2013
End date July 2017
Trial size 36 participants
Trial identifier NCT01748058, T87/2012


The aim of this study is to evaluate the efficacy and feasibility of active video gaming with regard to the promotion of physical activity and motor learning in children with cancer. Experienced fatigue, body mass index and the development of metabolic risk factors during treatment are also examined.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose prevention
Exercise based on active video gaming
exercise based on active video gaming
(No Intervention)

Primary Outcomes

Accelerometer, average counts of dynamic acceleration (physical activity)
time frame: 1 week at baseline and at 12 months

Secondary Outcomes

Movement assessment battery for children (M-ABC-2) scores (motor performance)
time frame: At baseline, 2, 6, 12 and 24 months
PedsQL Multidimensional Fatigue Scale scores (fatigue)
time frame: At baseline, 2, 6, 12 and 24 months
Blood sugar
time frame: At baseline, 2, 6, 12 and 24 months
Blood insulin
time frame: At baseline, 2, 6, 12 and 24 months

Eligibility Criteria

Male or female participants from 3 years up to 16 years old.

Inclusion Criteria: - cancer diagnose - treated with Vincristine in Turku University Hospital or Tampere University Hospital Exclusion Criteria: - other diseases limiting functional ability - not able to communicate

Additional Information

Official title Active Video Games to Promote Physical Activity, Motor Performance and Quality of Life in Children With Cancer: an Intervention Study With 2-year Follow-up
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Turku University Hospital.